F.D.A. Clears New Cancer-Fighting Drug From Roche

.

F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.


Latest News

BlackBerry is ending its internal hardware development to focus on software
Leaked image reveals some features of Google’s ‘Pixel’ handset
Report: Stock conditions for new iPhones at Apple retail stores will improve by
Apple’s new ‘macOS Sierra’ version brings Siri to desktop; unfolds several other
SquareTrade conducts dunk/drop tests on iPhone 7, iPhone 7 Plus, Galaxy Note 7
Samsung sued over exploded Galaxy Note 7 handset
Only 13% US Galaxy Note 7 users have exchanged their potentially explosive hands
Uber’s self-driving cars hit Pittsburg roads under a test program
Phil Schiller: Removal of headphone jack marks Apple’s desire for technological
Samsung, CPSC ask Galaxy Note 7 owners to stop using their handsets
Analyst: iPhone 7 will be packaged with EarPods which use Lightning connector
Spacecom may seek $50M or free flight from SpaceX to cover the cost of now-destr